SUPN Supernus Pharmaceuticals PE ratio, current and historical analysis

The current P/E ratio for Supernus Pharmaceuticals stock as of Apr 2, 2025 is 24.49. This is calculated based on the TTM EPS of $1.34 and the stock price of $32.82 per share.

SUPN PE ratio history

How has SUPN's PE ratio performed in the past

The average historical PE ratio of Supernus Pharmaceuticals for the last ten years is 74.58. The current price-to-earnings ratio of 24.49 is 67% less than the historical average. Analyzing the last ten years, SUPN's PE ratio reached its highest point in the Dec 2023 quarter at 1,447, when the price was $28.94 and the EPS was $0.02. The lowest point was recorded in the Mar 2020 quarter, when it reached 8.14 with a price of $17.99 and an EPS of $2.21.

Today
24.22
Average
74.58
Median
26.76
Minimum
8.14
Maximum
1,447

Supernus Pharmaceuticals PE ratio by year

Maximum annual increase: 4,483.47% in 2023

Maximum annual decrease: -98.13% in 2024

Year PE ratio PE change Price EPS
2024 26.99 -98.13% $36.16 $1.34
2023 1,447 4,483.47% $28.94 $0.02
2022 31.57 9.35% $35.67 $1.13
2021 28.87 176.53% $29.16 $1.01
2020 10.44 -4.92% $25.16 $2.41
2019 10.98 -29.62% $23.72 $2.16
2018 15.6 -55.77% $33.22 $2.13
2017 35.27 157.07% $39.85 $1.13
2016 13.72 -70.39% $25.25 $1.84
2015 46.34 N/A $13.44 $0.29
2014 N/A N/A $8.3 -$0.26
2013 N/A N/A $7.54 -$2.9
2012 N/A N/A $7.17 -$2.72
2011 N/A N/A N/A $31.39
2010 N/A N/A N/A -$26.38

Supernus Pharmaceuticals PE ratio by quarter (TTM)

Year PE ratio PE change Price EPS
Dec 2024 26.99 -6.51% $36.16 $1.34
Sep 2024 28.87 -90.29% $31.18 $1.08
Jun 2024 297.22 N/A $26.75 $0.09
Mar 2024 N/A N/A $34.11 -$0.29
Dec 2023 1,447 2,366.76% $28.94 $0.02
Sep 2023 58.66 54.17% $27.57 $0.47
Jun 2023 38.05 0.82% $30.06 $0.79
Mar 2023 37.74 19.54% $36.23 $0.96
Dec 2022 31.57 -33.79% $35.67 $1.13
Sep 2022 47.68 79.72% $33.85 $0.71
Jun 2022 26.53 14.11% $28.92 $1.09
Mar 2022 23.25 -19.47% $32.32 $1.39
Dec 2021 28.87 67.75% $29.16 $1.01
Sep 2021 17.21 6.17% $26.67 $1.55
Jun 2021 16.21 30.62% $30.79 $1.9

SUPN average PE ratio chart

What is the average PE ratio of SUPN for the past years

The current PE ratio of SUPN is under its 3, 5 and 10-year averages.

3-year avg
204.03
5-year avg
120.43
10-year avg
74.58
15-year avg
N/A

SUPN PE vs peers

What is SUPN's PE ratio compared to its peers

SUPN's PE ratio is less than its peer stocks LLY and JNJ, but it is above ABT's and UTHR's. Supernus Pharmaceuticals is currently trading at a lower PE ratio (24.49) than its peers average of 31.3.

Stock name PE ratio Market cap
UTHR UNITED THERAPEUTICS Corp 11.57 $13.74B
ABT Abbott Laboratories 17.26 $229.62B
SUPN Supernus Pharmaceuticals Inc 24.22 $1.81B
JNJ Johnson & Johnson 27.41 $385.34B
LLY ELI LILLY & Co 67.41 $751.69B
BMY Bristol Myers Squibb Co N/A $118.85B

Frequently asked questions

What is Supernus Pharmaceuticals's PE ratio?

The price to earnings ratio for SUPN stock as of Apr 2, 2025, stands at 24.49.

What is the 3-year average PE ratio for Supernus Pharmaceuticals (SUPN)?

Over the last 3 years, the average PE ratio for SUPN stock is 204.03.

What is the 5-year average PE ratio for Supernus Pharmaceuticals (SUPN)?

Over the last 5 years, the average PE ratio for SUPN stock is 120.43.

What is the highest PE ratio for SUPN?

The highest quarterly PE ratio in the last ten years has been 1,447 and it was in the Dec 2023 quarter.

How does the current PE ratio for SUPN compare to its historical average?

The current PE ratio of SUPN is 67% lower than the 10-year historical average.

How is SUPN's PE ratio calculated (Supernus Pharmaceuticals PE ratio formula)?

The P/E ratio is calculated by taking the latest stock price and dividing it by the earnings per share(EPS) for the last 12 months. As of today (Apr 2, 2025), Supernus Pharmaceuticals's share price is $32.82. The company's earnings per share for the trailing twelve months (TTM) ending Dec 2024 is $1.34. Therefore, Supernus Pharmaceuticals's price to earnings ratio for today is 24.49. PE RATIO(24.49) = STOCK PRICE($32.82) / TTM EPS($1.34)

All PE ratio stats are based on quarterly TTM periods, unless otherwise specified. Data from and Sharadar.